Halozyme Therapeutics, Inc. (NASDAQ:HALO) Short Interest Update

Halozyme Therapeutics, Inc. (NASDAQ:HALO) saw a large growth in short interest in the month of October. As of October 15th, there was short interest totalling 10,420,000 shares, a growth of 5.8% from the September 30th total of 9,850,000 shares. Currently, 8.3% of the company’s shares are short sold. Based on an average trading volume of 1,330,000 shares, the days-to-cover ratio is presently 7.8 days.

Analyst Ratings Changes

A number of analysts recently commented on HALO shares. TD Cowen raised their price target on Halozyme Therapeutics from $59.00 to $65.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. JPMorgan Chase & Co. lowered shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and lifted their target price for the company from $52.00 to $57.00 in a research note on Thursday, September 19th. Benchmark reissued a “buy” rating and issued a $60.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, August 8th. Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Finally, HC Wainwright reissued a “buy” rating and issued a $65.00 target price on shares of Halozyme Therapeutics in a research report on Friday, October 25th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $60.44.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Matthew L. Posard sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $55.72, for a total value of $557,200.00. Following the transaction, the director now directly owns 89,755 shares of the company’s stock, valued at $5,001,148.60. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Halozyme Therapeutics news, Director Matthew L. Posard sold 10,000 shares of the business’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $55.72, for a total value of $557,200.00. Following the transaction, the director now owns 89,755 shares in the company, valued at approximately $5,001,148.60. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Matthew L. Posard sold 9,881 shares of the stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $57.70, for a total transaction of $570,133.70. Following the sale, the director now owns 69,874 shares of the company’s stock, valued at approximately $4,031,729.80. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 89,881 shares of company stock worth $5,169,834 in the last ninety days. 2.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Halozyme Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HALO. GAMMA Investing LLC raised its stake in shares of Halozyme Therapeutics by 96.6% in the second quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 254 shares during the last quarter. International Assets Investment Management LLC bought a new stake in Halozyme Therapeutics in the 2nd quarter worth about $33,000. Whittier Trust Co. purchased a new position in Halozyme Therapeutics in the 1st quarter worth about $27,000. Skandinaviska Enskilda Banken AB publ bought a new position in Halozyme Therapeutics during the 2nd quarter valued at about $49,000. Finally, Toth Financial Advisory Corp purchased a new stake in shares of Halozyme Therapeutics during the 3rd quarter valued at about $57,000. 97.79% of the stock is owned by institutional investors.

Halozyme Therapeutics Trading Down 0.0 %

NASDAQ HALO opened at $50.57 on Friday. Halozyme Therapeutics has a 12 month low of $33.07 and a 12 month high of $65.53. The company has a current ratio of 7.41, a quick ratio of 6.21 and a debt-to-equity ratio of 5.19. The stock’s fifty day moving average price is $57.32 and its 200-day moving average price is $51.82. The stock has a market cap of $6.41 billion, a P/E ratio of 19.60, a P/E/G ratio of 0.50 and a beta of 1.27.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.18. Halozyme Therapeutics had a net margin of 38.62% and a return on equity of 195.80%. The business had revenue of $231.40 million during the quarter, compared to analysts’ expectations of $204.94 million. During the same period in the previous year, the company earned $0.68 earnings per share. The business’s revenue for the quarter was up 4.7% compared to the same quarter last year. As a group, equities analysts forecast that Halozyme Therapeutics will post 3.71 EPS for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.